Synlait sells assets to Abbott for US$178M to reduce debt

AUSTRALIA – Synlait Milk, a significant player in the nutrition and infant formula industry, has finalized the sale of its North Island assets, including the Pōkeno manufacturing facility, to Abbott Laboratories for about NZ$307 million (US$178 million).

The pivotal shareholder vote confirmed the necessary backing for this transaction, which is fundamental to addressing Synlait’s substantial debt load.

Crucially, the majority shareholder, Bright Dairy Holding, which holds a 65.25% stake, irrevocably committed its vote in favor of the sale.

The primary financial objective of the asset sale is to reduce debt. With net debt previously reported at around NZ$250.7 million, the proceeds from the NZ$307 million sale—targeted for completion by April 1, 2026—are intended to eliminate Synlait’s term debt.

This strengthening of the balance sheet comes despite the company reporting a full-year loss of NZ$39.8 million for the year ended July, a loss attributable primarily to prior manufacturing challenges and NZ$43.5 million in related costs.

Beyond financial stabilization, the divestment marks a profound strategic pivot for the dairy processor.

By consolidating operations around its South Island facilities, Synlait is refocusing on its core Canterbury strengths and high-value nutritional products, rather than wide-scale commodity processing.

This simplification also includes managing an “orderly transition” as its key customer, The a2 Milk Company, diversifies its supply chain—a necessary step as Synlait seeks to onboard multiple new advanced nutrition customers to secure future revenue streams.

This follows the company’s steps to bolster its financial liquidity by temporarily increasing its existing banking facilities by US$28.34 million (NZ$50 million).

The action directly addresses the persistent financial strain caused by costs associated with significant prior manufacturing challenges.

Despite this necessary capital injection, the company confirmed that it remains fully compliant with all its existing banking covenants.

The need for this increased working capital stems primarily from manufacturing challenges experienced at the company’s crucial Dunsandel site during the second half of the previous financial year.

These operational issues resulted in a substantial one-off cost of US$24.69 million (NZ$43.5 million).

Synlait’s planned lean working capital program for the current financial year became difficult to execute and manage due to negative cash flow impacts and ongoing expenses arising from earlier operational issues.

Subscribe to receive our email newsletters with the latest news and insights from Africa, the Middle East and around the world. SUBSCRIBE HERE